203 related articles for article (PubMed ID: 30170976)
1. Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
Shinde A; Li R; Amini A; Chen YJ; Cristea M; Dellinger T; Wang W; Wakabayashi M; Beriwal S; Glaser S
Gynecol Oncol; 2018 Oct; 151(1):82-90. PubMed ID: 30170976
[TBL] [Abstract][Full Text] [Related]
2. Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.
Bingham B; Orton A; Boothe D; Stoddard G; Huang YJ; Gaffney DK; Poppe MM
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1040-1050. PubMed ID: 28332987
[TBL] [Abstract][Full Text] [Related]
3. Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
Li R; Shinde A; Chen YJ; Amini A; Lee S; Dellinger T; Han E; Wakabayashi M; Nelson R; Beriwal S; Glaser S
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):373-382. PubMed ID: 29890264
[TBL] [Abstract][Full Text] [Related]
4. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival.
Ly D; Rowley BD; Dodson MK; Soisson PA; Jolles CJ; Gaffney DK; Sause WT
Gynecol Oncol; 2014 May; 133(2):250-5. PubMed ID: 24589416
[TBL] [Abstract][Full Text] [Related]
6. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
7. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis.
Rossi PJ; Jani AB; Horowitz IR; Johnstone PA
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):134-8. PubMed ID: 17855014
[TBL] [Abstract][Full Text] [Related]
9. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
[TBL] [Abstract][Full Text] [Related]
10. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
[TBL] [Abstract][Full Text] [Related]
12. Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis.
Stokes WA; Jones BL; Schefter TE; Fisher CM
Brachytherapy; 2018; 17(1):194-200. PubMed ID: 29097136
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
14. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
Rydzewski NR; Strohl AE; Donnelly ED; Kanis MJ; Lurain JR; Nieves-Neira W; Strauss JB
Cancer; 2016 Dec; 122(23):3724-3731. PubMed ID: 27509082
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
16. Oncological Outcomes of Stage II Endometrial Cancer: A Retrospective Analysis of 250 Cases.
Ozgul N; Boyraz G; Salman MC; Gultekin M; Yuce K; Ibrahimov A; Erturk A; Gungorduk K; Gulseren V; Sanci M; Turkmen O; Karalok A; Kimyon G; Turan T; Ozkan NT; Meydanli MM; Gungor T; Ayik H; Simsek T
Int J Gynecol Cancer; 2018 Jan; 28(1):161-167. PubMed ID: 28930810
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
18. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
[TBL] [Abstract][Full Text] [Related]
19. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
20. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
